Autosomal dominant GDAP1 mutation with severe phenotype and respiratory involvement: A case report

Adrian Rodriguez-Hernandez1*, Meagan Mayo2, Lilibeth Jauregui2 and Pooja Patel1,3

1Department of Neurology, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States, 2Department of Internal Medicine, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States, 3Department of Neurology, Marcus Neuroscience Institute, Boca Raton, FL, United States

Charcot Marie Tooth (CMT) is a heterogeneous group of genetic disorders characterized by progressive motor and sensory neuropathy. CMT is a multi-gene disorder with several possible mutations responsible for a wide range of clinical presentations. A specific mutation of the ganglioside-induced-differentiation-associated protein 1 (GDAP1) gene is associated with the axonal subtype of CMT (CMT2K) which is inherited in an autosomal dominant fashion, as well as the demyelinating subtype (CMT4A) which is inherited in an autosomal recessive pattern. Phenotypic disease expression is largely dependent on these inheritance patterns. While the autosomal recessive form (CMT4A) exhibits severe disease with an early onset, the autosomal dominant variant (CMT2K) tends to have milder phenotypes and a later onset. We describe an atypical presentation of a patient with severe CMT2K with rapidly progressive polyneuropathy, respiratory failure, and dysphonia. We suggest that this case will inspire further evaluation of disease heterogeneity and variants.

KEYWORDS
Charcot Marie Tooth, GDAP1, case report, CMT2K, neuropathy

Introduction

Charcot Marie Tooth (CMT) is characterized by a clinically and genetically miscellaneous group of neuropathies, spanning a variety of Mendelian inheritance patterns. Greater than 1,000 different mutations in 80 disease-associated genes have been identified (1). Mutations in the ganglioside-induced-differentiation-associated protein 1 gene (GDAP1) are responsible for a subgroup of the hereditary motor and sensory neuropathies seen in Charcot Marie Tooth (2).

GDAP1-related mutations may be inherited in an autosomal recessive pattern (more common) or in an autosomal dominant pattern. GDAP1 autosomal recessive inherited mutations, termed CMT4A, are characterized by demyelinating, axonal, or intermediate disease forms. CMT4A causes an early-onset, severe neuropathy that affects
all extremities and frequently leads to wheelchair dependence in young adult life (second-third decade). In the advanced stages of the disease, most of these patients acquire vocal cord paresis (unilateral or bilateral) and diaphragmatic weakness. On the other hand, autosomal dominant inherited mutations, termed CMT2K, are characterized by axonal disease and tend to have a more benign presentation characterized by slow progression, adult-onset, and more distal involvement. Most of these patients remain ambulant throughout their lives (3, 4). In isolated patients, CMT2K has been associated with characteristics more commonly associated with CMT4A, such as dysphonia or dysautonomia (5).

This case report describes an atypical course of CMT2K with rapidly progressive polyneuropathy, dysphonia, and respiratory failure in a patient with adult-onset, autosomal dominant disease.

**Case presentation**

A previously healthy and physically active 63-year-old male presented to the hospital due to a sensation of chest “heaviness” and dysphonia. Further history revealed that for the past 2 years, the patient had progressive paresthesias, cramping, and weakness beginning in the right lower extremity and then spreading to the left lower extremity and distal upper extremities bilaterally. He was now mostly confined to a wheelchair after being diagnosed with CMT 1 year ago.

The patient underwent a comprehensive screen of 81 genes associated with peripheral neuropathies. Genomic deoxyribonucleic acid (gDNA) was isolated from the patient’s whole blood. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides was carried out by a bait capture methodology using long biotinylated oligonucleotide probes followed by polymerase chain reaction (PCR) and Next-Generation sequencing. A compound heterozygous p. R120W mutation (also known as c.358C > T) was found at exon 3 of the GDAP1 gene (NM_018972.4); resulting from a C to T substitution at nucleotide position 358. This mutation

---

**TABLE 1.** Motor and sensory nerve conduction studies of the bilateral upper and lower extremities.

| Nerve Stimulation | Distance Recording | Latency (ms) | Amplitude (CMAP Mv; SNAP uV) | Velocity (m/s) |
|-------------------|--------------------|--------------|-------------------------------|---------------|
| Site              | (cm)               |              |                               |               |
|                   | Motor              | R           | L           | NL          | R           | L           | NL          | R           | L           | NL          |               |
| **Motor**         |                    |             |             |             |             |             |             |             |             |             |             |               |
| Median Wrist      | 22.5               | APB         | 5.2         | 5           | <4.2        | 0.3         | 0.8         | > 5         | 52          | 47          | >50         |
| Median Elbow      |                    |             | 9.5         | 9.8         |             | 0.3         | 0.9         |             |             |             |             |
| Ulnar Wrist       | 22                 | ADM         | 4.5         | 3.4         | <4.2        | 2           | 4.3         | > 5         | 50          | 49          | >53         |
| Ulnar Belbow      | 10                 | ADM         | 8.9         | 7.9         |             | 2           | 3.4         |             | 59          | 53          | >53         |
| Ulnar A Elbow     |                    | ADM         | 10.6        | 9.8         |             | 2.4         | 3.9         |             |             |             |             |
| Peroneal Fib Head |                    | EDB         | *NR         | *NR         | <6.1        | *NR         | *NR         | > 2.5       | *NR         | *NR         | >40         |
| Peroneal Pop fossa| 10                 | EDB         | *NR         | *NR         |             | *NR         | *NR         |             | *NR         | *NR         |             |
| Tibial Ankle      |                    | AHB         | *NR         | *NR         | <6.1        | *NR         | *NR         | > 3.0       | *NR         | *NR         | >35         |
| Tibial Pop fossa  |                    | AHB         | *NR         | *NR         |             | *NR         | *NR         |             | *NR         | *NR         |             |
| **Sensory**       |                    |             |             |             |             |             |             |             |             |             |             |               |
| Median Wrist      | 14                 | Dig II      | 4           | 3.6         | <3.6        | 38.4        | 28.5        | > 10        | 35          | 39          | >39         |
| Ulnar Wrist       | 14                 | Dig V       | 4.1         | 3.1         | <3.7        | 11.2        | 22.9        | >15         | 34          | 45          | >38         |
| Radial Forearm    | Wrist              | 2           | 2           | <3.1        | 26.5        | 24.4        | >15         |             |             |             |             |
| Sural Calf        | Ankle              | 4.4         | 4.6         | <4.0        | 6.1         | 4.7         | >5.0        | 32          | 30          | >35         |

ADM, abductor digiti minimi; AHB, abductor hallucis brevis; APB, abductor pollicis brevis; cm, centimeters; Dig, digit; EDB, extensor digitorum brevis; Fib, fibular; L, left; m/s, meters per second; ms, millisecond; NL, normal limit; Pop, popliteal; R, right; SNAP, sensory nerve action; uV, microvolt; NR, no response.
is described as “Pathogenic” (class 5) according to the ACMG guideline. A survey of the patient's family history also revealed an extensive incidence of CMT consistent with an autosomal dominant inheritance pattern. Disease was absent in both parents, with the patient's brother diagnosed at age five and the brother's daughter at age four. However, these family members presented with milder symptoms such as difficulty walking, arched feet, and wasting of the muscles in the lower extremities (Figure 1).

The patient's neurological examination revealed weakness of the bilateral upper extremities, bilateral intrinsic hand muscles, and right wrist extensors with compromised handwriting. Additionally, the patient had bilateral proximal leg weakness, including impaired foot flexion and dorsiflexion. There was generalized areflexia with reduced pinprick, vibration, and thermic sensation in all extremities (up to the knees and wrists). Based on these findings, the patient was assigned a CMT neuropathy scale of 24/36, which indicates severe neuropathy. In regard to the patient's initial concern of “chest heaviness”, chest X-ray was without abnormalities, although the patient was mildly tachypneic with the use of accessory muscles of respiration. The cardiac examination was unremarkable.

Laboratory tests did not reveal any acute abnormalities. Infections and acute coronary syndrome were excluded. Notably, there was an absence of paraprotein and a normal creatine kinase. Anti-Ach binding, anti-Ach blocking, antineuronal, antiganglioside, and anti-myelin-associated glycoprotein precursor antibodies were all negative. The patient refused lumbar puncture for cerebrospinal fluid (CSF) studies (he verbally explained normal CSF results from 1 year ago, although we were unable to obtain this report). MRI of the brain and cervical spine, as well CT of the chest, were without abnormalities.

On further workup, nerve conduction studies (NCS) demonstrated evidence of right median axonopathy, left median and right ulnar mixed type neuropathy, and demyelinating left ulnar neuropathy. There was also evidence of a severe generalized sensory and motor neuropathy of the lower extremities with an absence of F and H waves (Table 1). Due to the patient's decreased phonation and weak cough, intrahospital speech therapy suggested outpatient follow up for formal evaluation of probable vocal cord impairment.

With imminent threat to life ruled out, the patient was ultimately discharged. Unfortunately, he was lost to follow up.
| Study                  | Country | Number of Patients | Mutation(s)                        | Age onset (mean) | FDS Score (mean) | CMTNS (mean/range) | Muscle Weakness                                                                 | Wheelchair bound (number of patients) | Foot deformities (percentage of patients) | Sensory loss | Vocal cord paresis diaphragmatic weakness hoarseness | Electrophysiological studies |
|-----------------------|---------|--------------------|------------------------------------|------------------|------------------|--------------------|--------------------------------------------------------------------------------|----------------------------------------|------------------------------------------|--------------|-----------------------------------------------|---------------------------------|
| Kim et al. (6)        | Korea   | 7                  | R120W                               | 19.7 yrs         | 2.2              | 11.1/6–25          | All LL weakness (R22K > R120W) Hand weakness (in 5/7 patients)                  | No                                     | Yes (1)                                  | Yes (85.2%)  | No                                            | CMAP: normal (UL), decreased (LL) |
| Pakhrin et al. (7)     | China   | 9                  | V219G                               | 15.8 yrs         | NA               | NA/3–13            | Mild in LL                                                                     | No                                     | Yes (1)                                  | Yes (80%)     | No                                            | MNCV: 40.9 m/s                    |
| Sivera et al. (8)      | Spain   | 58                 | R120W                               | 23.8 yrs         | 1.3              | 7.3/0–26           | Distal LL                                                                     | No                                     | Yes (1)                                  | Yes (80%)     | No                                            | CMAP: decreased                  |
| Fu et al. (9)          | China   | 3                  | R120W                               | 3 yrs            | NA               | 12.5/12–13         | Distal and proximal                                                           | No                                     | No                                       | Yes (80%)     | No                                            | MNCV/CMAP in 2 patients (mean): 56.1 m/s/2.1 mv |
| Pezzini et al. (5)     | Italy   | 26                 | R120W                               | 19.8 yrs         | NA               | NA                 | Distal LL                                                                     | No                                     | No                                       | Yes (50%)     | No                                            | CMAP: Decreased (LL > UL)         |
| Auranen et al. (10)    | Finland | 14                 | R22S                               | 33.5 yrs         | NA               | NA                 | Distal UL (in 4/26 patients)                                                  | No                                     | No                                       | Yes (50%)     | No                                            | SNAP: Decreased (LL > UL)          |
| Chung et al. (11)      | Korea   | 2                  | Q218E                               | 24.5 yrs         | NA               | NA                 | Moderate in distal LL and UL                                                  | No                                     | No                                       | Yes (50%)     | No                                            | MNCV: mildly reduced/normal        |

CMTNS, Charcot-Marie-Tooth examination score; FDS, functional disability score; LL, lower limbs; UL, upper limbs; V, vibration; P, pain; NA, not available; yrs, years; CMAP, compound muscle action potential; MNCV, motor nerve conduction velocity; SNAP, sensory nerve action potential; SNCV, sensory nerve conduction velocity; m/s, meter/second; mV, millivolts.
and returned to the hospital 3 weeks later with worsening respiratory failure and dysphonia. At this time, arterial blood gas revealed persistent hypercapnia with hypoxemia, requiring Bilevel Positive Airway Pressure (BIPAP). Chest X-ray showed mild elevation of the left hemidiaphragm. An extensive workup for respiratory insufficiency excluded electrolyte abnormalities, myasthenia, autoimmune disease, substance abuse, infection, pulmonary embolism, spinal cord injury, and structural brain abnormalities. The patient developed worsening mental status in the setting of refractory hypercapnia and respiratory muscle fatigue. Per his wishes, the patient was not intubated and ultimately was transitioned to hospice care within 6 weeks of his initial presentation to this hospital (Table 2).

Discussion

Charcot-Marie Tooth presents heterogeneously with progressive motor and sensory polyneuropathy leading to weakness, muscle atrophy, loss of sensation, loss of deep tendon reflexes, and foot deformities. Mutations in the GDAP1 gene are responsible for both an autosomal recessive early-onset severe demyelinating form of CMT (CMT4A) and a late-onset dominant form (CMT2K)—such as was seen in our patient. Specifically, our patient possessed a p.R120w mutation located in coding exon 3 in the GDAP1 gene. This pathogenic mutation is the most common variant seen within CMT2K (3, 8). However, the severity of our patient’s clinical presentation was inconsistent with current knowledge of this CMT2K subtype (Table 3).

Although the clinical phenotype within CMT genotypes may differ between individuals in one family, this patient’s rapidly progressive disease in his 6th decade of life is a unique presentation of CMT2K. As described by Silveira et al. (8), the CMT2K usually does not present with respiratory failure, stridor, or vocal cord dysfunction. Rather, these are common characteristics of recessive forms (CMT4A). Therefore, extensive workup to rule out neuromuscular, infectious, toxic, cardiac, and metabolic etiologies of respiratory failure is essential in such atypical presentations. Although Abbousonan et al. (12) described multiple disorders of pulmonary function, sleep, and upper airway in patients with other CMT variants, these have not been documented in the CMT2K form. We believe our patient had a rapidly progressive restrictive pulmonary impairment secondary to diaphragmatic nerve dysfunction, as well as vocal cord impairment secondary to peripheral neuropathy affecting the vagus nerve and its laryngeal branches.

CMT2K is responsible for axonal neuropathy that is associated with (relatively) normal nerve conduction velocities (NCV), loss of myelinated axons, and regenerative sprouting. On the other hand, CMT4A causes demyelinating, axonal, or mixed type CMT that is characterized by segmental demyelination with a diffuse reduction in NCV (13). In addition to an unusually rapid onset and severe disease course, our patient also had an atypical neuropathy consisting of a mainly mixed pattern with a probable right concomitant carpal tunnel syndrome.

To our knowledge, we present the only documented case of CMT2K with adult-onset rapidly progressive respiratory failure and acute vocal cord dysfunction with evidence of mixed demyelinating and axonal neuropathy. This suggests that the phenotypic presentations of various types of CMT may extend beyond our current genotypic cognizance. This case will hopefully serve to motivate further research, disease understanding, and treatment optimization for those diagnosed with Charcot Marie Tooth.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

AR-H, MM, LJ, and PP contributed to the writing of the manuscript and critical revision of the manuscript. All authors gave important contributions to the final form of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Timmerman V, Strickland AV, Züchner S. Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the human genome project success. Genes. (2014) 5:13–32. doi: 10.3390/genes5010013

2. Cuesta A, Pedrola J, Sevilla T, García-Planells J, Chumillas MJ, Mayordomo F, et al. The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet. (2002) 30:22–5. doi: 10.1038/ng98

3. Zimon M, Baets J, Fabrizi GM, Jaakkola E, Kabirizka D, Pîch I, et al. Dominant GDAP1 mutations cause predominantly mild CMT phenotypes. Neurology. (2011) 77:540–8. doi: 10.1212/WNL.0b013e318228f70

4. Sevilla T, Jaijo T, Nauffal D, Collado D, Chumillas MJ, Vilchez JJ, et al. Vocal cord paresis and diaphragmatic dysfunction are severe and frequent symptoms of GDAP1-associated neuropathy. Brain. (2008) 131(Pt 11):3051–61. doi: 10.1093/brain/awn228

5. Pezzini I, Geroldi A, Capponi S, Gulli R, Schemone A, Grandis M, et al. GDAP1 mutations in Italian axonal Charcot-Marie-Tooth patients: Phenotypic features and clinical course. Neuro muscular Disorder. (2016) 26:26–32. doi: 10.1016/j.nmd.2015.09.008

6. Kim HS, Kim HJ, Nam SH, Kim SB, Choi YJ, Lee KS, et al. Clinical and neuroimaging features in Charcot-Marie-Tooth patients with GDAP1 mutations. J Clin Neurol. (2021) 17:52–62. doi: 10.3988/jcn.2021.17.1.32

7. Pakhrin PS, Xie Y, Hu Z, Li X, Liu L, Huang S, et al. Genotype-phenotype correlation and frequency of distribution in a cohort of Chinese Charcot-Marie-Tooth patients associated with GDAP1 mutations. J Neurol. (2018) 265:637–46. doi: 10.1007/s00415-018-8743-9

8. Sivera R, Frasquet M, Lupo V, García-Sobrino T, Blanco-Arias P, Parrado J, et al. Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain.Sci Rep. (2017) 7:6677. doi: 10.1038/s41598-017-06894-6

9. Fu J, Dai S, Lu Y, Wu R, Wang Z, Yuan Y, et al. Similar clinical, pathological, and genetic features in Chinese patients with autosomal recessive and dominant Charcot-Marie-Tooth disease type 2K. Neuromuscul Disorder. (2017) 27:760–5. doi: 10.1016/j.nmd.2017.04.001

10. Auranen M, Ylikallio E, Toppila J, Somer M, Kiuru-Enari S, Tyynismaa H. Dominant GDAP1 founder mutation is a common cause of axonal Charcot-Marie-Tooth disease in Finland. Neurogenetics. (2013) 14:123–32. doi: 10.1007/s10048-013-0358-9

11. Chung KW, Kim SM, Sunwoo IN, Cho SY, Hwang SJ, Kim J, et al. A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease. J Hum Genet. (2008) 53:360–4. doi: 10.1007/s10038-008-0249-3

12. Aboussouan LS, Lewis RA, Shy ME. Disorders of pulmonary function, sleep, and the upper airway in Charcot-Marie-Tooth disease. Lung. (2007) 185:1–7. doi: 10.1007/s00408-006-0053-9

13. Shy ME. Charcot-Marie-Tooth disease: an update. Curr Opin Neurol. (2004) 17:579–85. doi: 10.1097/00019052-200410000-00008